Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer

NCT00320749 is registered in ClinicalTrials.gov with Tony Bekaii-Saab as lead sponsor.

NCT NCT00320749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00320749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
Lead sponsor
Tony Bekaii-Saab
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2005
Completion date
January 31, 2011
Enrollment
21 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer